GEHC GE HealthCare Technologies Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$62.04

Period return

-19.85 (-24.24%)

Volume

2.9M

2026-07-21O $61.93 H $63.08 L $61.87 C $62.04MA5 $63.37MA20 $64.32MA60 $63.56MA120 $69.7

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 07. 29.Highin 8 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 21.MediumHOLD2 months ago
UBS: Neutral
US analyst rating / recommendation change.
2026. 05. 01.LowHOLD3 months ago
JP Morgan: Neutral
US analyst rating / recommendation change.
2026. 05. 01.LowHOLD3 months ago
Citigroup: Neutral
US analyst rating / recommendation change.
2026. 05. 01.MediumHOLD3 months ago
Goldman Sachs: Neutral
US analyst rating / recommendation change.
2026. 05. 01.LowHOLD3 months ago
Barclays: Equal-Weight
US analyst rating / recommendation change.
2026. 05. 01.LowBUY3 months ago
Evercore ISI Group: Outperform
US analyst rating / recommendation change.
2026. 04. 30.LowBUY3 months ago
Wells Fargo: Overweight
US analyst rating / recommendation change.
2026. 04. 30.LowBUY3 months ago
BTIG: Buy
US analyst rating / recommendation change.
2026. 04. 21.LowBUY3 months ago
BTIG: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $79.63 · 19 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 07. 29.	After market close (AMC)	$1.03	—	—	$5.26B	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$1.23	—	—	$4.78B	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$2.77	—	—	$14.35B	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$1.75	—	—	$9.49B	Reported

GE HealthCare Technologies Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 21.	UBS	—	Upgrade	Sell → Neutral	—	UBS: Sell → Neutral
2026. 05. 01.	JP Morgan	—	Maintain	Neutral → Neutral	—	JP Morgan: Neutral
2026. 05. 01.	Citigroup	—	Maintain	Neutral → Neutral	—	Citigroup: Neutral
2026. 05. 01.	Goldman Sachs	—	Downgrade	Buy → Neutral	—	Goldman Sachs: Buy → Neutral
2026. 05. 01.	Barclays	—	Maintain	Equal-Weight → Equal-Weight	—	Barclays: Equal-Weight
2026. 05. 01.	Evercore ISI Group	—	Maintain	Outperform → Outperform	—	Evercore ISI Group: Outperform